39 search results for Interleukin-18
| # | SuperPathway Name | Genes Count | Relevance Score | |||||
|---|---|---|---|---|---|---|---|---|
| 1 | Interleukin-1 family signaling | 153 | 2.392 | |||||
|
||||||||
| 2 | IL-1 Family Signaling Pathways | 158 | 1.173 | |||||
|
||||||||
| 3 | Cytokine Signaling in Immune system | 732 | 1.173 | |||||
|
||||||||
| 4 | Innate Immune System | 2025 | 1.173 | |||||
|
||||||||
| 5 | IL27-mediated signaling events | 60 | 1.016 | |||||
|
||||||||
| 6 | IL12-mediated signaling events | 85 | 1.016 | |||||
|
||||||||
| 7 | IL12 signaling mediated by STAT4 | 27 | 1.016 | |||||
|
||||||||
| 8 | Immune response IL-23 signaling pathway | 160 | 1.016 | |||||
|
||||||||
| 9 | Akt Signaling | 682 | 0.830 | |||||
|
||||||||
| 10 | Interleukin-37 signaling | 21 | 0.830 | |||||
|
||||||||
| 11 | PAK Pathway | 686 | 0.830 | |||||
|
||||||||
| 12 | MIF Mediated Glucocorticoid Regulation | 681 | 0.830 | |||||
|
||||||||
| 13 | ERK Signaling | 1185 | 0.830 | |||||
|
||||||||
| 14 | THC Differentiation Pathway | 40 | 0.830 | |||||
|
||||||||
| 15 | TGF-Beta Pathway | 653 | 0.830 | |||||
|
||||||||
| 16 | Inflammatory bowel disease signaling | 43 | 0.830 | |||||
|
||||||||
| 17 | Programmed Cell Death | 213 | 0.587 | |||||
|
||||||||
| 18 | TYROBP causal network in microglia | 60 | 0.587 | |||||
|
||||||||
| 19 | Toll-Like receptor Signaling Pathways | 133 | 0.587 | |||||
|
||||||||
| 20 | Cellular roles of Anthrax toxin | 19 | 0.587 | |||||
|
||||||||
| 21 | Development and heterogeneity of the ILC family | 32 | 0.587 | |||||
|
||||||||
| 22 | T-cell activation SARS-CoV-2 | 116 | 0.587 | |||||
|
||||||||
| 23 | Nucleotide-binding oligomerization domain (NOD) pathway | 41 | 0.587 | |||||
|
||||||||
| 24 | Overview of interferons-mediated signaling pathway | 168 | 0.587 | |||||
|
||||||||
| 25 | Cytosolic sensors of pathogen-associated DNA | 103 | 0.587 | |||||
|
||||||||
| 26 | Immune response_IL-12 signaling pathway | 25 | 0.587 | |||||
|
||||||||
| 27 | Interleukin-4 and Interleukin-13 signaling | 108 | 0.587 | |||||
|
||||||||
| 28 | Inflammasomes | 32 | 0.587 | |||||
|
||||||||
| 29 | Selective expression of chemokine receptors during T-cell polarization | 15 | 0.587 | |||||
|
||||||||
| 30 | Innate Lymphoid Cells Differentiation | 80 | 0.587 | |||||
|
||||||||
| 31 | MSP-RON Signaling | 48 | 0.587 | |||||
|
||||||||
| 32 | SARS-CoV-2 mitochondrial chronic oxidative stress and endothelial dysfunction | 17 | 0.587 | |||||
|
||||||||
| 33 | RIPK1-mediated regulated necrosis | 60 | 0.587 | |||||
|
||||||||
| 34 | Interleukin-10 signaling | 47 | 0.587 | |||||
|
||||||||
| 35 | IL1 and megakaryocytes in obesity | 24 | 0.587 | |||||
|
||||||||
| 36 | Infectious disease | 1747 | 0.587 | |||||
|
||||||||
| 37 | Hypertrophy model | 20 | 0.587 | |||||
|
||||||||
| 38 | Corticotropin-releasing hormone signaling pathway | 91 | 0.587 | |||||
|
||||||||
| 39 | ADORA2B mediated anti-inflammatory cytokines production | 419 | 0.587 | |||||
|
||||||||